
Head of the Russian Government Dmitri Medvedev visited today CJSC BIOCAD's commercial manufacturing facility for mAb-based therapeutic proteins.  This private facility is unique in Russia and Easter Europe. It produces monoclonal antibodies-based APIs for biological products that are widely used in treating oncological and autoimmune disorders.  The visit occurred in the context of the Presidium's meeting of the Russian Presidential Council on Innovations and Modernization. The focus of this meeting was on innovative developments in medical equipment and pharmaceutical industry.

The company currently employs over 700 people, 150 of whom are researchers and investigators working at BIOCAD's labs. BIOCAD 2013 sales were close to $ 90 m. The company has subsidiaries and representation in Belarus, Brazil, China, India, Ukraine, and the U.S.

Copyright ©2014 MarketWatch, Inc.  All rights reserved.

Intraday Data provided by SIX Financial Information and subject to terms of use .                 Historical and current end-of-day data provided by SIX Financial Information. Intraday data                 delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc.                 All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More                 information on NASDAQ traded symbols and their current financial status. Intraday                 data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM)                 from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is                 at least 60-minutes delayed. All quotes are in local exchange time.
